3 dated market items. Most recent: Compounded GLP-1 access consolidates toward smaller operators (2026-06-15).
Market items track who is actually selling, which has changed more than the medicine has.
Why market developments matter here
The large consumer platforms have largely left compounded GLP-1, and what remains at the cheap end is a field of smaller operators with variable disclosure. Brand recognition no longer does the diligence for you.
This matters for reading older comparisons: several programmes still ranked in round-ups no longer sell the product being compared. Check the verification date on any list before trusting its order.
All market items
Compounded GLP-1 access consolidates toward smaller operators
As the large consumer platforms exit, the cheap end of the market is increasingly served by…
Microdose protocols spread, and they are not comparable to standard dosing
Several programs now sell fractional-dose plans at lower prices. They do not map onto the…
Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest telehealth platforms exits…
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.